2.07
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GANX Giù?
Forum
Previsione
Gain Therapeutics Inc Borsa (GANX) Ultime notizie
Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease - The Manila Times
Is Gain Therapeutics Inc. stock cheap at current valuationPortfolio Performance Report & Pattern Based Trade Signal System - newser.com
How to forecast Gain Therapeutics Inc. trends using time seriesTrade Volume Summary & Weekly High Momentum Picks - newser.com
Will Gain Therapeutics Inc. stock benefit from sector rotation2025 Stock Rankings & Expert Curated Trade Setups - newser.com
Applying big data sentiment scoring on Gain Therapeutics Inc.Weekly Gains Report & AI Driven Price Forecasts - newser.com
What does recent volatility data suggest for Gain Therapeutics Inc.Earnings Performance Report & AI Driven Stock Movement Reports - newser.com
Intraday pattern recognizer results for Gain Therapeutics Inc.July 2025 PostEarnings & Stepwise Entry and Exit Trade Signals - newser.com
Gain Therapeutics (NASDAQ:GANX) Given Sell (E+) Rating at Weiss Ratings - MarketBeat
Gain Therapeutics Supports Reliable Data Management In Labs - Kalkine Media
Gain Therapeutics (NASDAQ:GANX) Given New $7.00 Price Target at Maxim Group - Defense World
Is Gain Therapeutics Inc a good long term investmentVolume Spike Alerts & Small Budget Big Profits - earlytimes.in
Maxim Group Maintains Gain Therapeutics (GANX) Buy Recommendation - Nasdaq
Maxim Group Raises Price Target for Gain Therapeutics (GANX) to - GuruFocus
Gain Therapeutics reports preliminary Phase 1b data for Parkinson’s drug GT-02287 - Investing.com
Stock Traders Buy High Volume of Gain Therapeutics Call Options (NASDAQ:GANX) - MarketBeat
Gain Therapeutics reports positive early data from Parkinson’s trial - Investing.com
Gain Therapeutics reports positive early data from Parkinson’s trial By Investing.com - Investing.com Australia
Gain Therapeutics Reports Positive Interim Data from Phase 1b Study of GT-02287 in Parkinson’s Disease - Quiver Quantitative
Gain Therapeutics Presents Initial Data from Phase 1b Clinical Study of GT-02287 in Parkinson’s Patients at International Congress of Parkinson’s Disease and Movement Disorders® - Stock Titan
What to do if you’re stuck in Gain Therapeutics Inc.Breakout Watch & Daily Stock Trend Watchlist - newser.com
Gain Therapeutics, Inc. (NASDAQ:GANX) Short Interest Up 61.6% in September - MarketBeat
Detecting price anomalies in Gain Therapeutics Inc. with AITrade Analysis Report & Verified Stock Trade Ideas - newser.com
Does Gain Therapeutics Inc. stock trade at a discount to peers2025 Breakouts & Breakdowns & Community Shared Stock Ideas - newser.com
Is it time to cut losses on Gain Therapeutics Inc.July 2025 Pullbacks & AI Optimized Trading Strategy Guides - newser.com
Gain Therapeutics (NASDAQ:GANX) versus Karyopharm Therapeutics (NASDAQ:KPTI) Head-To-Head Review - Defense World
What moving averages say about Gain Therapeutics Inc.July 2025 Retail & Capital Efficiency Focused Ideas - newser.com
Applying Wyckoff theory to Gain Therapeutics Inc. stockWall Street Watch & Free Community Supported Trade Ideas - newser.com
Analyzing drawdowns of Gain Therapeutics Inc. with statistical tools2025 Major Catalysts & Capital Efficiency Focused Strategies - newser.com
Can technical indicators confirm Gain Therapeutics Inc.’s reversal2025 Trading Recap & Reliable Volume Spike Trade Alerts - newser.com
What drives Gain Therapeutics Inc stock priceRisk Management Strategies & Investment Timing Techniques - earlytimes.in
What analysts say about Gain Therapeutics Inc stockEarnings Surprise Analysis & Superior Portfolio Growth - earlytimes.in
How to escape a deep drawdown in Gain Therapeutics Inc.Market Rally & Weekly Breakout Opportunity Watchlist - newser.com
What TG Therapeutics, Inc.'s (NASDAQ:TGTX) 26% Share Price Gain Is Not Telling You - simplywall.st
Custom strategy builders for tracking Gain Therapeutics Inc.Gap Up & Free Reliable Trade Execution Plans - newser.com
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):